Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Study sponsor: Minerva Neurosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-12Estimated
Enrollment · participants380Estimated
Source updated2026-11-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.